<DOC>
	<DOCNO>NCT02237508</DOCNO>
	<brief_summary>The pharmacokinetics study aim evaluate safety Z7200 ( budesonide/formoterol ) comparison Symbicort Turbohaler ( budesonide/formoterol ) , assess bioequivalence two product . Namely study compare total systemic bioavailability ( indicator safety ) , compare pulmonary bioavailability ( possible surrogate indicator efficacy ) . This study perform healthy subject .</brief_summary>
	<brief_title>A Clinical Study Evaluate Z7200 ( Budesonide/Formoterol ) Pharmacokinetics Profile Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Charcoal</mesh_term>
	<criteria>Main Male female 18 45 year age . If female , currently pregnant/breast feeding/ attempt become pregnant negative serum pregnancy test , nonchildbearing potential childbearing potential , willing commit use consistent acceptable method birth control childbearing potential sexually active Body mass index ( BMI ) 18.5 29.9 kg/m² inclusive body weight ≥50 kg . Main FEV1 value le 80 % predict value FEV1/FVC ratio &lt; 0.7 . History current evidence clinically significant disease disorder capable alter absorption , metabolism , distribution elimination drug . History current evidence clinically significant disease include , limited : cardiovascular , hepatic , renal , haematological , neuropsychological , endocrine , gastrointestinal pulmonary . Presence glaucoma , cataract , ocular herpes simplex , malignancy , regardless clinical significance current stability disease . History presence silent infection , include positive test HIV1 , HIV2 , Hepatitis B Hepatitis C. Bacterial viral infection upper respiratory tract ( include common cold flu ) , sinus , middle ear within 2 week dose . Lower respiratory tract infection/pneumonia within past 3 month . Presence disease condition regular concomitant treatment ( include vitamin herbal product ) know interfere absorption , distribution , metabolism excretion drug . Screening haemoglobin value le 1g/dL ULN ( 10g/L ) History recurrent vasovagal collapse . History anaphylactic/anaphylactoid reaction . History seizures include febrile seizure exclude childhood febrile convulsion . Unable demonstrate proper inhalation technique involve use delivery device screen . Exposure investigational drug within 90 day Screening Visit . Known suspect hypersensitivity idiosyncratic reaction steroid , β2 agonist , lactose monohydrate , leucine Tween 80 . History allergy milk protein . Use inhale corticosteroid within 30 day systemic corticosteroid within 60 day Screening Visit . Use medication herbal medicine strong cytochrome P450 3A4 ( CYP3A4 ) inhibitors inducer within 30 day prior Screening Visit Any clinically significant abnormal laboratory value physical finding may interfere interpretation test result cause health risk subject he/she participates study . Use caffeine contain beverage 600 mg caffeine/day . Current smoker exsmokers stop smoke less 10 year . Recent current ( suspect ) drug abuse positive result drug abuse test . Recent current alcohol abuse ( regular drinking 21 unit per week male 14 unit per week female [ 1 unit = 4 cl spirit equivalent ] ) . Predictable poor compliance , intolerance charcoal solution , inability communicate well study centre personnel inability participate treatment period . The subject able understand comply protocol requirement , instruction protocolstated restriction , participate clinical research study within previous three month previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>